Multiportal Arthroscopy-assisted Surgical Resection of Diffuse-type Tenosynovial Giant Cell Tumors in the Ankle Joint Yields Favorable Clinical Outcomes: A Retrospective Study

Abstract

Objective: Diffuse-type tenosynovial giant cell tumors (Dt-TGCTs) commonly occur in the knee joint and tend to recur postoperatively. However, limited clinical data are available on ankle joint involvement especially associated multiportal arthroscopic treatment outcomes. The purpose of this study was to report the clinical results of multiportal arthroscopy-assisted resection of Dt-TGCTs of the ankle.

Methods: We retrospectively reviewed the clinical data of 33 patients with Dt-TGCT of the ankle who underwent multiportal arthroscopic treatment between August 2011 and December 2020. Clinical follow-up included the visual analogue scale (VAS) score, American Orthopedic Foot and Ankle Society (AOFAS) score, Kofoed score, and recurrence rate to assess surgical outcomes. The number of patients who achieved the patient acceptable symptom state (PASS) based on the AOFAS score was also examined. Additionally, the patients were categorized into two groups based on the final surgical approach: Group A who underwent multiportal arthroscopic synovectomy and Group AO who underwent combined arthroscopic and open surgical excision. Intergroup comparisons were conducted. Intraoperative characteristics, such as the number of patients with involvement of the tarsal tunnel and fibularis tendon and the Outerbridge grading of cartilage damage, were recorded to assess the selection of surgical procedures.

Results: Among the 33 patients, 15 were assigned to Group A, and 18 were in Group AO. The median follow-up duration for the 33 patients was 77 months (range, 28–142 months). The median VAS score was 1 (range, 0–4), the AOFAS score was 96 (range, 65–100), and the Kofoed score was 96 (range, 67–100). A total of 27 patients (82%) achieved PASS based on AOFAS scores, while five patients (15%) had recurrence. No statistically significant difference was observed between the two groups in recurrence rate, follow-up VAS score, AOFAS score, Kofoed score, or number of patients who reached the PASS (p > 0.05). In the AO group, 16 cases of Dt-TGCT involved the tarsal tunnel, and 11 cases involved the fibularis tendon. All these patients exhibited extension beyond the joint. In contrast, only one patient in Group A had involvement of the tarsal tunnel. Statistically significant differences were observed between the groups (p < 0.001).

Conclusion: This study demonstrated that, with the assistance of a multiportal arthroscopic approach, surgical excision of Dt-TGCT in the ankle resulted in favorable clinical outcomes with a relatively low recurrence rate. Additionally, patients with extra-articular involvement were more likely to require concomitant open surgery.

Keywords

Ankle / Arthroscopy / Diffuse-type tenosynovial giant cell tumor / Recurrence / Synovectomy

References

[1] Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. Lancet Oncol. 2019; 20(6): 877–886.

[2] West RB, Rubin BP, Miller MA, Subramanian S, Kaygusuz G, Montgomery K, et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc Natl Acad Sci U S A. 2006; 103(3): 690–695.

[3] Fernandez-Flores A. Cannibalism in a benign soft tissue tumor (giant-cell tumor of the tendon sheath, localized type): a study of 66 cases. Romanian journal of morphology and embryology =. Rev Roumaine Morphol Embryol. 2012; 53(1): 15–22.

[4] Li X, Xu Y, Zhu Y, Xu X. Surgical treatment for diffused-type giant cell tumor (pigmented villonodular synovitis) about the ankle joint. BMC Musculoskelet Disord. 2017; 18(1): 450.

[5] Gelhorn HL, Tong S, McQuarrie K, Vernon C, Hanlon J, Maclaine G, et al. Patient-reported symptoms of Tenosynovial Giant cell tumors. Clin Ther. 2016; 38(4): 778–793.

[6] Spierenburg G, Lancaster ST, van der Heijden L, Mastboom MJL, Gelderblom H, Pratap S, et al. Management of tenosynovial giant cell tumour of the foot and ankle. Bone Joint J. 2021; 103-b(4): 788–794.

[7] Stevenson JD, Jaiswal A, Gregory JJ, Mangham DC, Cribb G, Cool P. Diffuse pigmented villonodular synovitis (diffuse-type giant cell tumour) of the foot and ankle. Bone Joint J. 2013; 95-b(3): 384–390.

[8] Çevik HB, Kayahan S, Eceviz E, Gümüştaş SA. Tenosynovial giant cell tumor in the foot and ankle. Foot Ankle Surg. 2020; 26(6): 712–716.

[9] Siegel M, Bode L, Südkamp N, Kühle J, Zwingmann J, Schmal H, et al. Treatment, recurrence rates and follow-up of Tenosynovial Giant cell tumor (TGCT) of the foot and ankle-a systematic review and meta-analysis. PLoS One. 2021; 16(12): e0260795.

[10] Barnett JR, Rudran B, Khan A, O’Reilly-Harbidge S, Patel S, Malhotra K, et al. Outcomes of Tenosynovial Giant cell tumor of the foot and ankle. Foot Ankle Int. 2023; 44(10): 1013–1020.

[11] Guo Q, Shi W, Jiao C, Xie X, Jiang D, Hu Y. Results and recurrence of pigmented villonodular synovitis of the ankle: does diffuse PVNS with extra-articular extension tend to recur more often? Knee Surg Sports Traumatol Arthrosc. 2018; 26(10): 3118–3123.

[12] Colman MW, Ye J, Weiss KR, Goodman MA, McGough RL 3rd. Does combined open and arthroscopic synovectomy for diffuse PVNS of the knee improve recurrence rates? Clin Orthop Relat Res. 2013; 471(3): 883–890.

[13] Sung KS, Ko KR. Surgical outcomes after excision of pigmented villonodular synovitis localized to the ankle and hindfoot without adjuvant therapy. J Foot Ankle Surg. 2015; 54(2): 160–163.

[14] Ottaviani S, Ayral X, Dougados M, Gossec L. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum. 2011; 40(6): 539–546.

[15] Tsukamoto S, Zucchini R, Staals EL, Mavrogenis AF, Akahane M, Palmerini E, et al. Incomplete resection increases the risk of local recurrence and negatively affects functional outcome in patients with tenosynovial giant cell tumor of the hindfoot. Foot Ankle Surg. 2020; 26(7): 822–827.

[16] Wąsik J, Stołtny T, Pasek J, Szyluk K, Pyda M, Ostałowska A, et al. Effect of Total ankle arthroplasty and ankle arthrodesis for ankle osteoarthritis: a comparative study. Med Sci Monitor: Int Med J Exp Clin Res. 2019; 25: 6797–6804.

[17] Anderson MR, Baumhauer JF, DiGiovanni BF, Flemister S, Ketz JP, Oh I, et al. Determining success or failure after foot and ankle surgery using patient acceptable symptom state (PASS) and patient reported outcome information system (PROMIS). Foot Ankle Int. 2018; 39(8): 894–902.

[18] Goh GS, Tay AYW, Rikhraj IS, Koo K. Defining the patient acceptable symptom state for the American Orthopaedic Foot & Ankle Society score following hallux valgus surgery. Foot Ankle Surg. 2021; 27(5): 528–534.

[19] Yao L, Li Y, Li T, Fu W, Chen G, Li Q, et al. What are the recurrence rates, complications, and functional outcomes after multiportal arthroscopic synovectomy for patients with knee diffuse-type Tenosynovial Giant-cell tumors? Clin Orthop Relat Res. 2024; 482(7):1218–1229.

[20] Brien EW, Sacoman DM, Mirra JM. Pigmented villonodular synovitis of the foot and ankle. Foot Ankle Int. 2004; 25(12): 908–913.

[21] Ma X, Shi G, Xia C, Liu H, He J, Jin W. Pigmented villonodular synovitis: a retrospective study of seventy five cases (eighty one joints). Int Orthop. 2013; 37(6): 1165–1170.

[22] Saxena A, Perez H. Pigmented villonodular synovitis about the ankle: a review of the literature and presentation in 10 athletic patients. Foot Ankle Int. 2004; 25(11): 819–826.

[23] Bickels J, Isaakov J, Kollender Y, Meller I. Unacceptable complications following intra-articular injection of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis. J Bone Joint Surg Am. 2008; 90(2): 326–328.

[24] Lee M, Mahroof S, Pringle J, Short SC, Briggs TW, Cannon SR. Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy. Int Orthop. 2005; 29(6): 403–405.

[25] Baniel C, Yoo CH, Jiang A, von Eyben R, Mohler DG, Ganjoo K, et al. Long-term outcomes of diffuse or recurrent Tenosynovial Giant cell tumor treated with postoperative external beam radiation therapy. Pract Radiat Oncol. 2023; 13(3): e301–e307.

[26] Cassier PA, Gelderblom H, Stacchiotti S, Thomas D, Maki RG, Kroep JR, et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer. 2012; 118(6): 1649–1655.

[27] Healey JH, Tap WD, Gelhorn HL, Ye X, Speck RM, Palmerini E, et al. Pexidartinib provides modest pain relief in patients with Tenosynovial Giant cell tumor: results from ENLIVEN. Clin Orthop Relat Res. 2023; 481(1): 107–116.

RIGHTS & PERMISSIONS

2024 The Author(s). Orthopaedic Surgery published by Tianjin Hospital and John Wiley & Sons Australia, Ltd.